

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (cancelled).

Claim 2 (original): A method for reducing an oxytocin-mediated action in a subject comprising administering to the subject an amount of thiazolidinedione effective to reduce the oxytocin-mediated action in the subject.

Claim 3 (original): The method of claim 2, wherein the oxytocin-mediated action is induction of labor in a pregnant subject.

Claim 4 (original): The method of claim 2, wherein the oxytocin-mediated action is induction of uterine cramps.

Claim 5 (original): The method of claim 2, wherein the oxytocin-mediated action is induction of milk letdown.

Claim 6 (original): The method of claim 2, wherein the oxytocin-mediated action is induction of prostaglandin release.

Claim 7 (original): The method of claim 2, wherein the subject is a mammal.

Claim 8 (original): The method of claim 2, wherein the thiazolidinedione comprises troglitazone.

Claim 9 (original): The method of claim 2, wherein the thiazolidinedione comprises pioglitazone, BRL49653, or a compound related to troglitazone.

Claim 10 (original): The method of claim 2, wherein the thiazolidinedione is dispersed in a pharmacologically acceptable form.

Claim 11 (original): The method of claim 10, wherein said thiazolidinedione is administered locally.

Claim 12 (original): The method of claim 10, wherein said thiazolidinedione is administered parenterally.

Claim 13 (original): The method of claim 12, wherein said thiazolidinedione is administered intravenously.

Claim 14 (original): The method of claim 11, wherein the thiazolidinedione is administered intravaginally.

Claim 15 (original): The method of claim 3, further comprising administering a tocolytic agent.

Claim 16 (original): The method of claim 15, wherein said tocolytic agent comprises a beta-mimetic, magnesium sulfate, a prostaglandin inhibitor, or a calcium-blocking agent.

Claim 17 (original): The method of claim 16, wherein the prostaglandin inhibitor is indomethacin.

Claim 18 (original): The method of claim 17, wherein the calcium-blocking agent is nifedipine.

Claim 19 (original): The method of claim 15, wherein the tocolytic agent and thiazolidinedione are administered simultaneously.

Claims 20-21 (cancelled).